09/28/2020
Researchers from the new Center for Immunotherapy and Precision Immuno-Oncology will leverage their expertise with Cleveland Clinic’s world-class resources to help advance patient care and research into new therapies related to many cancer types, including head and neck cancers.
With one of the largest cell production facilities in the state and a robust biorepository, Cleveland Clinic aims to lead the future of head and neck cancer and cancer therapies, including immunotherapies. Cleveland Clinic has made a strong commitment—over $80 million—to fund its new Center for Immunotherapy and Precision Immuno-Oncology (CITI), which will support immunotherapy research and care related to many types of cancers. Hear from Brian Burkey, MD, vice chair of the Head & Neck Institute, and Timothy Chan, MD, PhD, director of CITI, about how the two teams will work together to advance head and neck cancer translational research, with the ultimate goal to enhance patient care and outcomes.
Chair, Center for Immunotherapy & Precision Immuno-Oncology
Director, Global Center for Immunotherapy, Cleveland Clinic
Co-Director, National Center for Regenerative Medicine
Program Leader, Immune Oncology Program, Case Comprehensive Cancer Center
Sheikha Fatima bint Mubarak Endowed Chair in Immunotherapy
Lab Profile
The honor recognizes Dr. Chan's contributions to the advances of medical science, healthcare and public health.
Dr. Chan will serve as the core investigator at Cleveland Clinic, one of four institutions working together as part of this collaborative study funded through Aligning Science Across Parkinson’s.
The gift from the United Arab Emirates will advance cancer and pathogen research globally.
The future of health starts with your support. Donations supply researchers with the tools, space and staff they need to think big.
Give to Cleveland Clinic